Corpus Intelligence IC Memo — VALLEY PRESBYTERIAN HOSPITAL 2026-04-26 15:54 UTC
IC Memo — VALLEY PRESBYTERIAN HOSPITAL
Investment Committee Memorandum | CA | 333 beds | Grade C | EBITDA uplift $34.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

VALLEY PRESBYTERIAN HOSPITAL

CCN 050126 | LOS ANGELES, CA | 333 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

VALLEY PRESBYTERIAN HOSPITAL is a 333-bed suburban community hospital in LOS ANGELES, CA with $462.0M in net patient revenue and a -22.7% operating margin. The hospital serves a payer mix of 18.7% Medicare, 15.5% Medicaid, and 65.7% commercial.

Thesis: Undervalued. Our ML models identify $34.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -22.7% to -15.3% (+736bps).

Net Revenue HCRIS$462.0M
Current EBITDA COMPUTED$-104.9M
Operating Margin COMPUTED-22.7%
Occupancy HCRIS55.1%
Revenue / Bed COMPUTED$1.4M
Net-to-Gross HCRIS48.6%
Distress Probability ML52.0%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
166
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -22.7% places it below the state median. Among 166 size-comparable peers (166-666 beds), the median margin is -3.8%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (166-666), prioritizing same-state peers. 166 hospitals in the comp set.

HospitalStateBedsRevenueMargin
VALLEY PRESBYTERIAN HOSPITAL (Target)CA333$462.0M-22.7%
STANFORD HEALTH CARECA657$6.76B3.7%
UC DAVIS MEDICAL CENTERCA666$3.28B-11.5%
RONALD REAGAN UCLACA446$2.62B-6.8%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
LOS ANGELES GENERAL MEDICAL CECA596$1.96B10.2%
UCI MEDICAL CENTERCA397$1.90B-2.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
RADY CHILDRENS HOSPITAL - SAN CA401$1.82B14.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $34.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$9.7M+210bp18mo
Cost to Collect4.5%2.5%$9.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$9.1M+198bp12mo
A/R Days Reduction5200.0%3800.0%$5.6M+122bp9mo
Clean Claim Rate88.0%96.0%$296K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$9.7M
Cost to Collect
$9.2M
Denial Rate Reduction
$9.1M
A/R Days Reduction
$5.6M
Clean Claim Rate
$296K
Total EBITDA Uplift$34.0M
Current EBITDA$-104.9M
+ RCM Uplift+$34.0M
Pro Forma EBITDA$-70.9M
Current Margin-22.7%
Pro Forma Margin-15.3%
WC Released (1x)$17.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-161.4M$-351.9M0.00x-100.0%
Base (11x exit)10.0x11.0x$-161.4M$-439.5M0.00x-100.0%
Bull Case9.0x11.0x$-145.2M$-379.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-145.2M$-457.1M0.00x-100.0%
Bear Case11.0x10.0x$-177.5M$-469.5M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-177.5M$-574.1M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 52.0% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 166 hospitals with 166-666 beds
  • Same-state prioritization (n=167)
  • Comp margins: P25=-14.7% / P50=-3.8% / P75=4.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.